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Abstract: Background: Beta-toxin (CPB) is the major virulence factor of Clostridium perfringens type
C, causing hemorrhagic enteritis in newborn pigs but also other animals and humans. Vaccines
containing inactivated CPB are known to induce protective antibody titers in sow colostrum and
neutralization of the CPB activity is thought to be essential for protective immunity in newborn
piglets. However, no method is available to quantify the neutralizing effect of vaccine-induced
antibody titers in pigs. (2) Methods: We developed a novel assay for the quantification of neutralizing
anti-CPB antibodies. Sera and colostrum of sows immunized with a commercial C. perfringens type A
and C vaccine was used to determine neutralizing effects on CPB induced cytotoxicity in endothelial
cells. Antibody titers of sows and their piglets were determined and compared to results obtained
by an ELISA. (3) Results: Vaccinated sows developed neutralizing antibodies against CPB in serum
and colostrum. Multiparous sows developed higher serum and colostrum antibody titers after
booster vaccinations than uniparous sows. The antibody titers of sows and those of their piglets
correlated highly. Piglets from vaccinated sows were protected against intraperitoneal challenge with
C. perfringens type C supernatant. (4) Conclusions: The test based on primary porcine endothelial
cells quantifies neutralizing antibody activity in serum and colostrum of vaccinated sows and could
be used to reduce and refine animal experimentation during vaccine development.
Keywords: necrotizing enteritis; C. perfringens type C; beta-toxin; neutralizing antibodies; cell culture
assay; primary porcine endothelial cell
Key Contribution: The test system uses the neutralization capacity of antibodies towards the
biological activity of the C. perfringens beta-toxin. It can be used to show neutralizing activity of
serum and colostrum antibodies in animal experiments and thus reduce and refine such experiments.
1. Introduction
Clostridium (C.) perfringens type C causes necrotizing enteritis (NE) in animals but also humans [1].
The main and essential virulence factor of pathogenic strains is beta-toxin (CPB), a 35 kDa toxin
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belonging to the beta-pore-forming toxin family [2]. The toxin is responsible for endothelial damage
leading to acute and massive intestinal hemorrhage, necrosis of the small intestinal mucosa and acute
death of affected hosts [3–5]. It has long been known that immunoprophylaxis using vaccines based
on inactivated C. perfringens type C culture supernatants is effective in preventing the disease [6–8].
As the disease is primarily a problem for the porcine industry, commercially available vaccines
are readily used in veterinary practice. Sows are vaccinated during every gestation period and
newborn piglets are passively protected by antibodies taken up from the colostrum [9]. Although
C. perfringens type C secretes many different toxins [10], antibodies against CPB are most likely essential
for protective immunity, as the toxin is essential for disease development [11,12]. Because the pathogen
can persist for several years on farms [13] continuous vaccination combined with good management
and hygiene procedures is essential to maintain a low pathogen burden and to protect pig herds
from the re-occurrence of the disease [14]. According to Hogh [15] gilts need to be immunized twice,
at approximately days 70 and 100 of gestation, in order to induce a significant increase of anti-CPB
antibodies in the colostrum. Subsequently, multiparous sows should be re-vaccinated prior to each
farrowing in order to provide sufficient passive immunity to their piglets. This vaccination scheme is
believed to ensure protective antibody titers [15]. Antibody titers against CPB used to be evaluated
using mouse or guinea pig injection models [8,9,16–18], however, such methods should be replaced
by in vitro assays. Currently, ELISA tests for titration of total amounts of anti-CPB antibodies in
sera and colostrum can be applied [19]. These tests are mainly used during regulatory processes in
vaccine development and licensing, but do not differentiate toxin neutralizing from non-neutralizing
antibodies. Solanki et al. [20] recently used an in vitro neutralization assay on THP-1 cells to measure
neutralizing capacity of serum from mice immunized against CPB. We previously showed that cultured
primary porcine and human endothelial cells are highly sensitive to CPB, and that this toxicity can be
inhibited by neutralizing anti- CPB antibodies [3,4]. Therefore, we aimed to apply a cell culture assay
for the detection of neutralizing antibodies in serum and colostrum samples of pigs. The advantage of
a porcine endothelial cell-based assay over human THP-1 or HUVEC cells would be that cells used are
derived from the target species for which the vaccine is developed. In addition, porcine endothelial
cells closely resemble the natural target cells, which have been shown to be endothelial cells in the
intestinal mucosa [21]. The cell culture assay was used on serum and colostrum samples from a
laboratory vaccination trial for the licensing process of a new vaccine against C. perfringens type C.
2. Results
2.1. Total Anti-Beta-Toxin Antibodies Determined by ELISA
For this study, 10 pregnant gilts (sows in first pregnancy) were vaccinated using a newly developed
commercially available vaccine against C. perfringens type C (ENTEROPORC AC, IDT Biologika GmbH,
Germany) according to the manufacturer’s recommendation. As a control, 10 pregnant gilts received
2.0 mL of physiological NaCl at the same time points. The scheme of vaccination, serum and colostrum
sampling used is shown in Figure 1. To show the specificity of the test, another control of 3 pregnant gilts
were vaccinated using a commercially available vaccine against C. perfringens type A (CLOSTRIPORC
A, IDT Biologika GmbH, Germany), which does not contain beta-toxoid.
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no antibodies were detected in gilts of the vaccination group before the first vaccination (Figure 2a). 
After the first vaccination, 4 of 10 gilts showed low total antibody titers (range: 0.016-0.556 AU/ml, 
antibody units per ml, Figure 2a). In 9 of 10 gilt serum samples and all colostrum samples, antibody 
titers were detected after the second vaccination (range: 0.834-15 AU/ml, Figure 2a und 2b). All piglets 
of these gilts had detectable antibody titers, which decreased over the period of four weeks (Figure 
2c). After farrowing, the antibody titers of the sows were decreased (range: 0.021-5.06 AU/ml) 
compared to values ante partum (a.p.) and significantly increased after the booster vaccination 
administered during the second pregnancy (range: 4.25-37.5 AU/ml, Figure 2a). After this booster 
vaccination, the colostrum antibody titers were significantly higher compared to those at the end of 
the first pregnancy (Figure 2b). In addition, the piglets of the second litter had significantly higher 
antibody titers compared to piglets of the first litter from the same sows. Similar to piglets from the 
first litters, piglet antibody titers decreased over the period of 4 weeks post-partum (p.p.) (Figure 2c). 
In 170 out of 195 samples from the non-vaccinated control sows and their piglets, no anti-CPB 
antibodies were detected. In 15 samples very low positivity was detected by ELISA (range: 0.008-
0.096 AU/ml, Figure 2a, 2b, 2c).  
Figure 1. Immunization and sampling schedule for vaccination trial. Timeline of sample collection in
the vaccination trial; B0: before the initial immunization, B1: after the first immunization, B2: after the
second immunization, B3: before the booster vaccination during 2nd pregnancy, B4: after the booster
vaccination during 2nd pregnancy, P-B1: one week p.p., P-B2: 2 weeks p.p., P-B3: 3 weeks p.p., P-B4:
4 weeks p.p.; B: blood sample of the sow, Col: colostrum, P-B: blood samples of piglets.
In the control sera and colostrum, no antibodies against CPB were detected by ELISA. Likewise
no antibodies were detected in gilts of the vaccination group before the first vaccination (Figure 2a).
After the first vaccination, 4 of 10 gilts showed low total antibody titers (range: 0.016–0.556 AU/mL,
antibody units per mL, Figure 2a). In 9 of 10 gilt serum samples and all colostrum samples, antibody
titers were detected after the second vaccination (range: 0.834–15 AU/mL, Figure 2a,b). All piglets of
these gilts had detectable antibody titers, which decreased over the period of four weeks (Figure 2c).
After farrowing, the antibody titers of the sows were decreased (range: 0.021–5.06 AU/mL) compared
to values ante partum (a.p.) and significantly increased after the booster vaccination administered
during the second pregnancy (range: 4.25–37.5 AU/mL, Figure 2a). After this booster vaccination,
the colostrum antibody titers were significantly higher compared to those at the end of the first
pregnancy (Figure 2b). In addition, the piglets of the second litter had significantly higher antibody
titers compared to piglets of the first litter from the same sows. Similar to piglets from the first litters,
piglet antibody titers decreased over the period of 4 weeks post-partum (p.p.) (Figure 2c). In 170
out of 195 samples from the non-vaccinated control sows and their piglets, no anti-CPB antibodies
were detected. In 15 samples very low positivity was detected by ELISA (range: 0.008–0.096 AU/mL,
Figure 2a–c).
2.1.1. Cell Culture Assay
Based on our previous findings demonstrating that primary porcine aortic endothelial cells
(PAEC) are highly sensitive to recombinant CPB and that the cytotoxic effects can be eliminated by
neutralizing monoclonal anti-CPB antibodies [3], we developed a cell culture based neutralization
assay. In principle, upon pre-incubation of a constant amount of recombinant CPB (rCPB) with serum
or colostrum samples containing neutralizing anti-CPB antibodies, the cytotoxic effect of the toxin
should be inhibited.
In a first step we tested the specificity of the cell culture assay on serum and colostrum samples
of sows. 200 ng/mL rCPB were pre-incubated with serum or colostrum samples (1:2 dilution in cell
culture medium), resulting in 100 ng/mL rCPB, for one hour at room temperature. PAEC were then
incubated with these samples for 24 h and assessed by light microscopy (Figure 3). As positive controls,
rCPB was pre-incubated with the international standard anti-CPB serum or monoclonal anti-CPB
antibodies (10A2, USDA, Aimes Iowa) (Figure 3). Serum and colostrum samples of sows vaccinated
against C. perfringens type C showed inhibitory effects on the cytotoxicity of rCPB, indicating presence
of neutralizing antibodies against CPB. In contrast, serum and colostrum of sows vaccinated against
C. perfringens type A and serum and colostrum of non-vaccinated sows did not neutralize the cytotoxic
effect of rCPB on PAEC (Figure 3).
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Figure 2. Total anti-beta-toxin (CPB) antibodies determined by ELISA. (a) Progression of antibody titers
in sow serums measured by ELISA. B0: before the initial immunization, B1: after first immunization,
B2: after second immunization, B3: before booster vaccination during 2nd pregnancy, B4: after
booster vaccination during 2nd pregnancy. Asterisks indicate significant differences between groups
(repeated measures ANOVA, Tukey–Kramer Multiple-Comparison test). Antibody titers significantly
increased from B1 to B2 (p < 0.01), decreased from B2 to B3 (p < 0.01) and increased again fter the
booster immunization from B3 to B4 (p < 0.01). Antibody titers after the s cond pregnancy (B4) were
significantly h gher than after the first (B2) (p < 0.01). (b) Colostrum antibody titers after first (1) and
second (2) farrowing measured by ELISA. Titers after the second farrowing were significantly higher
(asterisks) compared to the first farrowing (p < 0.05) (repeated measures ANOVA, Tukey–Kramer
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Multiple-Comparison Test). (c) Progression of antibody titers in piglet serums 1 (P-B1), 2 (P-B2), 3 (P-B3),
and 4 weeks p.p. (P-B4) measured by ELISA. Asterisks indicate significant differences between groups
(repeated measures ANOVA, Tukey–Kramer Multiple-Comparison test). Mean antibody titers of the
second litter were significantly higher compared to the first litter in the vaccinated groups (p < 0.01 for
all time points). No neutralizing antibodies were detected in the non-vaccinated group.
We then determined neutralizing antibody levels of all sow and piglet samples of the vaccination
trial. 200 ng/mL rCPB were pre-incubated with two-fold serial dilutions of the respective serum
and colostrum samples, resulting in 100 ng/mL rCPB, followed by incubating PAEC for 24 h and
determination of cell viability. Using pre-incubations of 200 ng/mL rCPB with serial two-fold dilutions
of the World Health Organization International Standard Serum of equine origin (antibody titer
4770 international units per ml (IU/mL), National Institute for Biological Standards and Control,
Potters Bar, Hertfordshire, EN6 3QG, UK) we determined the minimal neutralizing antibody titer at
0.58 IU/mL. The antibody titer was calculated by multiplying the minimal neutralizing antibody titer of
0.58 IU/mL with the last dilution step of serum and colostrum samples providing 100% neutralization
of 100 ng/mL beta-toxin.
No neutralizing anti-beta-toxin antibodies were detected in any sample of the sows and piglets
from the non-vaccinated control group (Figure 4a–c). In the group vaccinated against C. perfringens type
C neutralizing antibodies were not detected in any serum from gilts before and after the first vaccination
(time points B0 and B1, Figure 4a). After the second vaccination (B2), neutralizing antibodies were
detected in the serum of 90% of the gilts (range: 2.385–19.08 IU/mL) (Figure 4a). Additionally, colostrum
of gilts contained neutralizing anti-CPB antibodies in a range from 4.77 to 610.56 IU/mL (Figure 4b).
The association between antibody titers of the colostrum and the serum can be described with the
following regression model: Log(Y + 0.01) = 0.67 + Log(X + 0.01)*0.88, where Y is the antibody titer
of the serum and X is the antibody titer of the colostrum (p-value < 0.01, R2 = 0.42, Spearman-rank
correlation coefficient r = 0.69, p-value = 0.01). Neutralizing antibodies were detected in 85% of the
serum samples from piglets of gilts. The titers ranged from 2.385 to 152.64 IU/mL (Figure 4c). Antibody
titers subsequently decreased over 4 weeks p.p. (Figure 4c). In 15% of these piglets, no neutralizing
effect was measured using the cell culture assay. In between the two pregnancies, the serum antibody
titers of the sows (time point B3) significantly decreased compared to the p.p. time point (Figure 4a).
In 50% of the serum samples from sows, no neutralizing effect was detected using the cell culture assay,
in the other 50%, the antibody titers ranged from 2.385 to 9.54 IU/mL. Four days p.p. of the second
farrowing (after booster vaccination 2 weeks a.p.) the neutralizing antibody titers were significantly
increased in all sows (range: 9.54–305.28 IU/mL) (Figure 4a). Colostrum antibody titers after the second
farrowing were significantly higher (range: 152.6–9768.96 IU/mL) than those from the first farrowing
(Figure 4b). The colostrum antibody titer at the second farrowing highly correlated with the serum
antibody titers p.p. The association between antibody titers of the colostrum and the serum can be
described with the following regression model: Log(Y + 0.01) = −0.42+ Log(X + 0.01)*0.78, where X is
the antibody titer of the serum and Y is the antibody titer of the colostrum (p-value < 0.01, R2 = 0.99,
Spearman-rank correlation coefficient r = 0.96, p-value > 0.01, Figure 4d). All serum samples of piglets
form the second litters contained neutralizing antibodies (range: 19.08–152.64 IU/mL). The mean
antibody titer in the first week p.p. of these piglets was 3.6 times higher compared to piglets from the
first litter (Figure 4c).
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Figure 3. Inhibitory effect on recombinant CPB (rCPB) mediated cytotoxicity in serum and colostrum
of sows vaccinated against C. perfringens type C. Left lane: Confluent porcine aortic endothelial cells
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(PAEC) were incubated for 24 h with cell culture medium containing no additives (medium), control
anti-CPB antibodies, or serum (1:2 volume dilutions) and colostrum (1:2 volume dilutions) samples
of sows treated as indicated. The right lane shows representative results of pre-incubation of
100 ng/mL rCPB with the same media and additives. Absence of cytopathic effects after pre-incubation
with respective samples indicated presence of specific neutralizing anti-CPB antibodies in serum
and colostrum samples of only those sows vaccinated against C. perfringens type C. Cells were
fixed in paraformaldehyde, stained with Hemacolor® and photographed under a light microscope
(magnification 100x).Toxins 2019, 11, x FOR PEER REVIEW 8 of 16 
 
 
Figure 4. Neutralizing anti-CPB antibody titers determined by cell culture assay. (a) Progression of 
neutralizing antibody titers determined by cell culture assay in sow serums. B0: before the initial 
immunization, B1: after first immunization, B2: after second immunization, B3: before booster 
vaccination during 2nd pregnancy, B4: after booster vaccination during 2nd pregnancy. Asterisks 
indicate significant differences between groups (repeated measures ANOVA, Tukey–Kramer 
Multiple-Comparison test). Antibody titers significantly increased from B1 to B2 (p<0.01), decreased 
from B2 to B3 (p<0.05) and increased again after the booster immunization from B3 to B4 (p<0.01). 
Antibody titers after the second pregnancy (B4) were significantly higher than after the first (B2) 
(p<0.01). (b) Neutralizing colostral antibody titers after first (1) and second (2) farrowing determined 
by cell culture assay. Titers after the second farrowing were significantly higher (asterisks) compared 
to the first farrowing (p <0.05) (repeated measures ANOVA, Tukey–Kramer Multiple-Comparison 
Figure 4. Neutralizing anti-CPB antibody titers determined by cell culture assay. (a) Progression of
neutralizing antibody titers determined by cell culture assay in sow serums. B0: before the initial
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immunization, B1: after first immunization, B2: after second immunization, B3: before booster
vaccination during 2nd pregnancy, B4: after booster vaccination during 2nd pregnancy. Asterisks
indicate significant differences between groups (repeated measures ANOVA, Tukey–Kramer
Multiple-Comparison test). Antibody titers significantly increased from B1 to B2 (p < 0.01), decreased
from B2 to B3 (p < 0.05) and increased again after the booster immunization from B3 to B4 (p < 0.01).
Antibody titers after the second pregnancy (B4) were significantly higher than after the first (B2)
(p < 0.01). (b) Neutralizing colostral antibody titers after first (1) and second (2) farrowing determined
by cell culture assay. Titers after the second farrowing were significantly higher (asterisks) compared
to the first farrowing (p < 0.05) (repeated measures ANOVA, Tukey–Kramer Multiple-Comparison
Test). (c) Progression of neutralizing antibody titers in piglet serums one (P-B1), two (P-B2), three
(P-B3) and four weeks p.p. (P-B4) determined by cell culture assay. Asterisks indicate significant
differences between groups (repeated measures ANOVA, Tukey–Kramer Multiple-Comparison test).
Mean antibody titers of the second litter were significantly higher compared to the first litter in the
vaccinated groups (p < 0.01 for all time points). No neutralizing antibodies were detected in the
non-vaccinated group. (d) Scatterplot and linear regression model (continuous line, equation in results)
of neutralizing antibody titers in vaccinated sows in serum p.p. of the second litter and colostrum
determined by cell culture assay. Units: Log(IU/mL + 0.01). Each dot represents samples from one
litter. One sow did not gain antibodies (value at lower left corner).
The International Units per ml measured by use of the cell culture assay strongly correlated with
the AU/mL measured by ELISA with a Spearman-rank correlation coefficient r = 0.92., p-value < 0.01
(Figure 5). Their association can be described with the following regression model: Log (Y + 0.01) =
−0.09 + Log (X + 0.01)*0.84, where X is the total antibodies in IUs measured by ELISA and Y is the
neutralizing antibodies measured by the cell culture (p-value < 0.01, R2 = 0.8984).
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Figure 5. Scatterplot and linear regression model (continuous line, equation in results) of total and
neutralizing antibody titers in serum and colostrum measured by ELISA and cell culture in all vaccinated
sows. Total antibody titer measured by ELISA in AU/mL and neutralizing antibody titer measured
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individual sample.
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2.1.2. Challenge Experiment
The results of the challenge experiments are shown in Table 1. In total 20 piglets from 10 vaccinated
gilts and 16 piglets from 8 control gilts were challenged in the first trial. No piglets from vaccinated
gilts exhibited serious clinical signs associated with the intoxication. In the control group 13 out of
16 (81.25%) challenged piglets showed distinct clinical signs. 11 piglets out of 16 (68.75%) had to be
euthanized due to the severity of clinical signs. In the second trial 18 piglets from 9 vaccinated gilts
and 20 piglets from 10 control gilts were challenged. All piglets from vaccinated gilts were protected.
In the non-vaccinated control group 19 out of 20 (95.00%) challenged piglets showed distinct clinical
signs. Out of 20 piglets, 18 (90.00%) had to be euthanized.
Table 1. Results of the laboratory vaccination and challenge trials.
Morbidity Rate Mortality Rate
Trial Group Sows (n) Piglets (n) n In % n In %
1 2 x vaccination 10 20 0 * 0 0 * 0
1 Control 8 16 13 81.25 11 68.75
2 3 x vaccination 9 18 0 * 0 0 * 0
2 Control 10 20 19 95.00 18 90.00
* Significant differences between the vaccinated group and control group (Fisher’s exact test, level of significance
p < 0.05 (Fisher’s exact test).
3. Discussion
We describe the establishment of a cell culture assay for the specific detection and quantification
of neutralizing antibodies against the C. perfringens beta-toxin (CPB). This test system makes use of
the high susceptibility of primary porcine aortic endothelial cells to CPB. As CPB is the essential
virulence factor of C. perfringens type C [11,12], antibody mediated neutralization of the toxin can be
regarded as a reliable measure for protective immunity induced by vaccines against C. perfringens type
C. The specificity of our test was shown by detecting neutralizing anti-CPB antibodies in serum of
sows vaccinated against C. perfringens type C, but not C. perfringens type A or non-vaccinated animals.
Sensitivity was shown by accurately detecting low and high antibody titers, respectively. The antibody
titers measured by our cell culture assay strongly correlated with those determined by ELISA. This
demonstrates that both methods are suitable to detect anti-CPB antibody titers in the serum and
colostrum of pigs. The cell culture assay has the advantage of demonstrating the toxin neutralizing
capacity of antibodies. For C. perfringens type C vaccine development and licensing the European
Pharmakopoe lists a mouse neutralization assay (MNT) to prove the induction of immunity, which
neutralizes the toxic activity of C. perfringens type C supernatants [22]. Our test system offers the
possibility of an alternative approach to such animal experiments. In this respect, the use of cell cultures
derived from the target species of the vaccine which in addition, closely resembles those cells targeted
by the toxin in vivo [21], is an advantage of the test system. Although THP-1 cells have been shown to
be a suitable readout system a dose of 2.5 µg rCPB/2 × 104 cells in 100 µl medium was used to achieve
toxicity in these cells [20]. Compared to THP-1 cells, the CPB dose required for intoxication of primary
porcine endothelial cells used in our assay was 10 ng rCPB/ 4 × 104 cells in 100 µL medium. Thus,
porcine endothelial cells seem to be more susceptible to rCPB and might therefore represent a more
reliable readout system. Although our new assay requires the propagation of primary cell cultures,
stock cultures are readily produced [3] and therefore the test can easily be performed in laboratories
equipped for cell culture work. Alternatively, commercially available primary human endothelial cells,
such as HUVEC, could be used as these cells are reported to be highly sensitive to CPB and the toxic
effect of CPB can be inhibited by neutralizing antibodies [4,23]. These cells would be easier to obtain;
however, they are not derived from the target species for which the vaccine is produced for. In addition,
porcine endothelial cells might exhibit less individual variations between different donor pigs as they
can be derived from pigs with more similar and uniform genetic backgrounds compared to HUVEC.
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Like HUVEC, primary porcine endothelial cells cannot be propagated indefinitely and from our
experience should not be used after 10 subsequent passages (Wyder, personal observation). Generation
of a cell line by immortalization of porcine endothelial cells, which then could be propagated more
readily, might circumvent this problem. Thus, further research and development on this cell culture
assay could lead to a system that can reduce, refine, or replace lethal animal testing during the process
of vaccine development for use in porcine production.
Furthermore, we demonstrated the development of neutralizing anti-beta-toxin antibody titers in
sows and piglets in a laboratory vaccination study, comprised of two subsequent trials in gilts and
multiparous sows. The study was not designed to determine the minimal protective antibody level
for oral infections in piglets, however the initial immunization of gilts generated a mean colostrum
antibody titer in a range that was reported to protect piglets [15]. When sows were boostered during
their second pregnancy, the mean colostrum antibody titer and the mean antibody titer in piglet sera
were significantly higher at farrowing compared to the first farrowing, which supports the currently
recommended vaccination scheme with one booster vaccination prior to every following farrowing [15].
Challenge experiments using an intraperitoneal application model in piglets showed that antibody
titers achieved in piglets were fully protective after two and three immunizations during the first
and second pregnancy. Although this assay does not determine protection against disease after oral
infection, which is the natural route of infection [1], results indicate that achieved antibody levels in
piglets are protective. Our assays could now be used to determine minimal protective neutralizing
antibody titers to prevent disease after oral infection. However, such experiments would have to
take different infectious doses into account, as we have no exact knowledge about the amount of
C. perfringens type C ingested by piglets from the environment under natural conditions.
Taken together we demonstrate that ELISA and cell culture assays can be applied to demonstrate
total but also neutralizing antibody levels against C. perfringens beta-toxin in serum and colostrum
samples of pigs. These methods could be used to demonstrate protective antibody levels in sows and
piglets in vaccination trials but also in practice to investigate herd immunity against C. perfringens type
C enteritis.
4. Materials and Methods
4.1. Vaccination Trial
The laboratory vaccination study, including the challenge experiments, was conducted according
to the German law for Animal Welfare and registered under the animal experiment announcement
Nos. IDT-A-03b-2012 and IDT-A-04b-2012. In the first trial 20 pregnant gilts (German Landrace x
Duroc, 8–10 months old) were randomly assigned to two groups of 10 sows each. Group 1 (vaccination
group) was immunized against C. perfringens type C with the newly developed C. perfringens type A/C
toxoid vaccine ENTEROPORC AC batch 001 07 14 (IDT Biologika GmbH, Germany). The vaccine
contains min. 125 relative units (rU) alpha toxoid, min. 3354 rU/mL beta toxoid and 770 rU beta2
toxoid per milliliter. For the first farrowing, sows received two separate injections of 2.0 mL of the
vaccine intramuscularly (i.m.) 5 and 2 weeks a.p. Two sows developed transient mastitis and could
not be included in the sampling. For a follow up study (second trial) the same sows were inseminated
again and received a booster immunization with 2.0 mL of the vaccine i.m. two weeks before the
second farrowing. Group 2 (non-vaccinated control group) received 2.0 mL of physiological NaCl i.m.
at the same time points. Blood samples from each gilt were collected before (B0) and after the first
immunization (B1) and 4 days p.p. (B2). During the second pregnancy, blood samples were taken
before the booster vaccination (B3) and 4 days p.p. Colostrum was collected at birth (Col1 and Col2).
In addition, blood samples were collected from two piglets per litter: one (P-B1), two (P-B2), three
(P-B3), and four weeks p.p (P-B4) (Figure 1). Specificity of the cell culture assay was tested using
samples of sows immunized with CLOSTRIPORC A (IDT Biologika GmbH, Germany) containing
inactivated C. perfringens type A supernatant, including alpha- and beta2-toxoids but no beta-toxoid.
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The same vaccination scheme as for ENTEROPORC AC was applied. Serum and colostrum samples of
three sows (B0, B1, B2, colostrum) and six piglets (P-B1) were tested. Serum and skimmed milk were
generated by centrifugation of blood samples (3500× g, 10 min) and colostrum (23,000× g, 20 min).
The samples were stored in aliquots at −20 ◦C until examination.
4.2. Recombinant Beta-Toxin
The clone for expression of the recombinant beta-toxin (rCPB) was established at the Institute of
Hygiene and Infectious Diseases (Justus Liebig University Giessen, Germany). For toxin production
an agitated culture in LB broth was performed (37 ◦C, 180 rpm). Toxin production was induced at
an optical density of 0.5 (OD550) by addition of 0.05 µg/mL of anhydrotetracycline followed by a
further cultivation (4 h, 32 ◦C, 180 rpm). The cells were then separated via centrifugation (5000× g,
25 min, 10 ◦C) followed by a resuspension in physiological saline solution. Cell lysis was performed
with a FRENCH-Pressure-Cell-Press (Sim-Aminco Spectronic Instruments, USA) during two passages
(pressure >900 psi). The purification of the toxin was done with a StrepTactin-Matrix (Institute of
Bioanalytics, Göttingen, Germany). Quantification of rCPB was performed as described by Gurtner et
al. [3]. Aliquots were stored at −20 ◦C.
4.3. ELISA
The ELISA was performed as a sandwich-ELISA. Microtiter plates (MaxiSorp®, Nunc GmbH,
Wiesbaden, Germany) were coated with a 1:800 dilution of a monoclonal anti-CPB antibody (clone
3A6, IDT Biologika GmbH). Unspecific binding sites were blocked with milk powder supplemented
phosphate buffered saline (PBS). Subsequently, the primary antibody was saturated with rCPB
(>17,000 AU/mL, in house preparation). One well without addition of rCPB on every microtiter
plate served as negative control for subtraction of the unspecific binding capacity of the serum. This
was followed by a washing step with PBS supplemented with Tween 20 (PBST) (Merck, Germany).
The sera and a standard serum (positive control; hyperimmune serum of a pig) were then added
in 2-fold dilution series (incubation for 1 h at 37 ◦C). After a further washing step in PBST, a goat
anti-pig horseradish peroxidase conjugated antibody (1:10,000, Bethyl Laboratories, USA) was added.
SeramunBlau (Seramun Diagnostica GmbH, Wolzig, Germany) was used as chromogen according to
the manufacturer’s instruction. The reaction was stopped with 0.5 M sulfuric acid. The plates were
subsequently measured at a wavelength of 450 and 620 nm using a plate reader (Sunrise, Tecan Group
Ltd., Männedorf, Switzerland). The antibody titer of the samples are given in antibody units per ml
(AU/mL).
4.4. Cell Culture Assay
Primary porcine aortic endothelial cells (PAEC) were cultured on 96 well plates in Dulbecco’s
Modified Eagle Medium (DMEM + Glutamax, Gibco®) containing 1% L-Glutamin, 100 U/mL penicillin,
100 u/mL streptomycin, 0.25 µg/mL Amphotericin B, and 10% fetal calf serum, at 37 ◦C and 5% CO2.
1 × 104 cells/cm2 were seeded 5 days prior to the experiment and grown to confluency. 60µl of cell
culture medium with a toxin concentration of 200 ng/mL rCPB of the same batch as used for ELISA
testing were incubated with 60µl of two fold serial dilutions of serum or colostrum samples (in cell
culture medium) for one hour at room temperature. PAEC were then incubated with 100 µL of these
samples for 24 h at 37◦ with 5% CO2. This resulted in a final incubation of appr. 4 × 104 cells with a
total of 10 ng CPB in 100 µL medium (100 ng/mL).
Monoclonal mouse anti-CPB antibody 10A2 (MAb-CPB, USDA, Aimes Iowa, USA) and the
C. perfringens beta antitoxin, 2nd International Standard (2CPBETAAT; from NIBSC, Potters Bar,
Hertfordshire, England; antibody concentration of 4770 IU/mL) were used as positive controls for
neutralizing antibodies. Serum and colostrum of non-vaccinated sows were used as negative controls.
Cell viability was determined using a redox dye (CellTiter Blue® (CTB), Promega Corporation,
Madison, USA). 10µl of the CTB were added to each well and incubated for 4 h at 37◦ with 5%
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CO2. The proportion of viable cells was then measured as fluorescence at 560 and 590 nm using the
Enspire® plate reader (EnSpire® Multimode Plate Reader by PerkinElmer). A blank fluorescence
composed of a dead cell monolayer (cell death induced by beta-toxin), and serum or colostrum dilutions
was measured for each dilution step. Fluorescence values for individual wells were determined by
subtracting the blank value from the total fluorescence value of each well. The fluorescence value
of each well was then correlated to the fluorescence values of the corresponding control serum or
colostrum dilution. The World Health Organization International Standard Serum of equine origin
(antibody titer 4770 IU/mL, National Institute for Biological Standards and Control, Potters Bar,
Hertfordshire, EN6 3QG, UK) neutralized 100 ng/mL of CPB at 0.58 IU/mL. This value was multiplied
with the last dilution step of serum and colostrum samples providing 100% neutralization of 100 ng/mL
beta-toxin. The International Standard Serum was dissolved in PBS and diluted with completed
medium. Following the fluorescence measurements, cells were fixed with 4% paraformaldehyde and
stained with rapid staining dye (Hemacolor®). Cytopathic effects and confluency of the monolayers
were evaluated by light microscopy and the percentage of intact cells was estimated independently by
two investigators.
4.5. Challenge Experiments
For the production of the challenge material, C. perfringens type C strain No. MB-yellow-130
was cultivated in TVS medium. After separation of the biomass by centrifugation (10,000× g),
the supernatant was concentrated by ultrafiltration and ammonium sulfate precipitation. The pellet
was resuspended in PBS, sterile filtrated, freeze dried and stored at 2 to 8 ◦C.
For the challenge experiment, one vial of the freeze-dried toxin was dissolved in 19.0 mL sterile
TVS medium. Two piglets from each of the vaccinated and control sows at the 1st and 2nd farrowing
were challenged by intraperitoneal (i.p.) injection at the 2nd day of life with 2.0 mL of the dissolved
toxin. After intoxication the clinical parameters general condition, posture, behavior, milk uptake,
nutritional status of the piglets, respiration, ascites, skin turgor, and diarrhea were assessed until the
end of the suckling period (Table 2). While assessing the clinical parameters an animal was deemed to
be sick when: (i) it had a summative clinical score of 5 or higher; (ii) it developed ascites; (iii) it lagged
behind its littermates in weight development due to the symptoms triggered by the intoxication (runts).
The piglets were euthanized according to animal welfare reasons if the following occasions were
present: (i) acute onset of clinical disease: disturbed general condition combined with a somnolence,
lack of milk uptake and/or a failure of weight gain; (ii) chronic progression of clinical disease: severe
ascites and/or an impaired breathing in combination with a stagnation or rather a decrease in body
weight. At the end of the trial, the number of diseased and euthanized piglets in the vaccinated and
control group were evaluated and compared using Fisher’s Exact Test. In accordance with monograph
04/2013/0360 (Ph. Eur.) protection was deemed to be shown if ≤20% of the piglets of the vaccinated
sows and ≥80% of the piglets of the control sows were considered sick or had to be euthanized
after intoxication.
Table 2. Examination parameters of the piglets following intoxication.
Parameter Clinical Findings and Score





0 = normal, body supported equally on all 4 limbs, animal moves
physiologically
1 = unstable gait, kyphosis
2 = animal lies permanently
Behaviour
0 = normal, animal is alert
1 = apathetic
2 = somnolent
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Table 2. Cont.
Parameter Clinical Findings and Score








1 = increased respiratory rate






0 = < 1 s (after pulling skin fold in neck region)
1 = 1 – 3 s
2 = > 3 s
Diarrhoea
0 = no, formed faeces
1 = yes, pasty
2 = yes, runny
3 = yes, pasty or runny, bloody, or black feces
* Piglets were weighed twice weekly.
4.6. Statistics
Statistics were done using the NCSS software (Nashville, USA, http://www.ncss.com) and SPSS
(SPSS Inc.). Shapiro–Wilk test was used to test normality. As the antibody titers were not normally
distributed, the logarithm transformation (log(y + 0.01)) was used. The differences in antibody titers
between the treatment groups were tested by means of a repeated measures analysis of variance, taking
the animal identification number as a subject variable. The post hoc test used for multiple comparisons
was the Tukey–Kramer Multiple-Comparison Test. The level of significance was set to 0.05. Besides,
the associations between the antibody titers in serum and colostrum and measured by ELISA and
the cell culture assay was evaluated by means of linear regression of the log transformed variables
and Spearman–Rank correlation coefficients. The differences between the treatment groups in the
challenge experiment were tested using Fisher’s Exact Test.
4.7. Ethics Approval
This study was conducted according to the German law for Animal Welfare and approved on
25 March 2012 under the animal experiment announcement Nos. IDT-A-03b-2012 and IDT-A-04b-2012.
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